StemCell Therapy

Dr Alexandra Butler/Principal Investigator at Qatar Biomedical Research Institute, part of Hamad Bin Khalifa University, talks about efforts to tackle

What is diabetes?Diabetes is a disease that occurs when there is an inability to produce adequate amounts of insulin (a hormone produced by beta cells in the pancreas) to maintain blood glucose levels within normal limits, and it represents a major medical, social, and economic burden worldwide.The prevalence of diabetes has reached epidemic proportions globally, with 424.9mn affected adults aged 20-79, representing 8.8% of the global adult population.This figure is predicted to rise to 628.6mn by 2045, affecting almost 10% of the worldwide adult population. Type 2 diabetes accounts for 90 to 95% of diabetes cases, with type 1 diabetes accounting for about 5%. However, half of those with type 2 diabetes have not been diagnosed.In Qatar, 20% of the population is affected by diabetes (type 2 accounting for 90% of those) with a projected rise to 24% in the next two decades. Diabetes in Qatar affects all segments of society, from the young to the elderly, and places a significant social and economic burden on Qatari society.What is the difference between type 1 and type 2 diabetes, and are there other types?The reasons underlying the inability to produce adequate amounts of insulin depend upon the type of diabetes.Type 1 is essentially a total insulin deficiency due to the destruction of beta cells by the bodys immune system. Type 2 is a complex disease characterised by insulin resistance and insulin deficiency. The degrees of resistance and deficiency vary, but insulin deficiency is key to developing diabetes.Gestational diabetes is a form of diabetes that can develop during pregnancy as pregnancy is a state of increased insulin resistance and these women have a higher risk of developing type 2 diabetes later in life.There are also genetic defects of beta cell function and insulin action, such as Maturity Onset Diabetes of the Young (MODY).Some conditions, such as diseases of the exocrine pancreas, can cause secondary diabetes as can certain drugs, corticosteroids being a prime example.

What are the symptoms of diabetes?Those with type 1 diabetes may experience thirst, a frequent need to urinate, weight loss, fatigue, blurred vision, ketoacidosis (a life-threatening conditions where the body starts breaking down fat at a rapid rate), and infections.Type 2 diabetes can lead to thirst, frequent urination, and malaise, but symptoms are usually much milder and many individuals with type 2 diabetes do not know they have the disease until they are tested.In certain circumstances, it can be difficult to distinguish between type 1 and type 2 diabetes (see Table 1). Distinguishing the type of diabetes can be particularly difficult in younger patients who are treated with insulin, but clinically appear to have type 2 diabetes, and older patients with late onset of diabetes who require insulin and share characteristics of patients with type 1 diabetes where Latent Autoimmune Diabetes of Adulthood (LADA) should be considered.What role is Qatar Biomedical Research Institute (QBRI) playing in relation to diabetes research?The genetic risks for type 2 diabetes are likely to be different for Qataris compared to other Asians and Europeans. Therefore, identification of factors that are associated with the high prevalence of type 2 diabetes in the Qatari population is an important focus of ongoing research at the Diabetes Research Center (DRC) at Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University.Diabetic complications are costly, extremely difficult to manage, and lead to increased mortality rates. Diabetic patients are also at increased risk of neurological impairment and certain forms of cancer, so identifying biomarkers that predict the future development of diabetes and/or its related complications is imperative.Accordingly, biomarker discovery is a major focus of the ongoing research at the DRC. With the advent of stem cells, the concept of mimicking nature to generate new beta-cells to reverse diabetes has emerged, although more work needs to be done to allow for safe and effective therapy.In collaboration with the Harvard Stem Cell Institute, the Stem Cell group at DRC is working towards developing safe and effective stem cell-derived therapy to meet the needs of diabetic patients in Qatar.The underlying causes of insulin resistance are not addressed by any current therapy.The DRC is also investigating the mechanisms of insulin resistance to identify new targets for drug discovery. The mechanisms underlying the susceptibility of kidney, retina, peripheral nerve and arteries to damage in diabetes are yet to be proven, but the DRC has made advances towards understanding these. The centre is paving the way towards improved biomarkers and focused treatments, or precision medicine for diabetes, in order to tackle this globally devastating disease.

Can we prevent or reverse diabetes if we follow a healthy lifestyle?In the Gulf region, the diabetes epidemic is largely fuelled by obesity and sedentary lifestyles. Type 1 diabetes is not reversible but type 2 is largely preventable and can be reversed in its earlier stages by adopting a healthy lifestyle, the mainstays of which include regular exercise, a healthy diet and maintaining a healthy weight.Anyone can suffer from diabetes and those with affected family members are at an increased risk. It is therefore a good idea to follow your doctors advice as to the frequency of testing for diabetes.

See the rest here:
Diabetes has reached epidemic proportions, yet many don't know they suffer from it - Gulf Times

Get your news fix on happenings outside the pool with the latest Beyond the Lane Lines. With each edition, we collect personal stories, little known facts and general items of interest from around the world. Read on and learn something new this week.

#1 Joseph Schooling Launches Skincare Line

Olympian Joseph Schooling took gold in the mens 100m fly at the 2016 Games in Rio and has been a superstar in his home nation ever since. The 24-year-old former Texas Longhorns latest accomplishment is taking place outside the pool, where the Singaporean just launched his own line of skincare products.

Teaming up with aesthetic doctor Dr. SM Yuen from Atlas Medical Laser & Aesthetics Clinic, Schooling has helped create a range of unisex beauty products that he hopes will help educate consumers on the importance of taking care of their skin.

My teammates used to laugh at me because I was the only one on the team who moisturized. We used to have our training [sessions] at the Toa Payoh pool where the chlorine level was super high. When I got out of the pool, my skin looked ashy and flaky. Our hair used to be bleached blonde and I had white patches all over my body and neck, said Schooling. So at age 11, taking care of my skin became a daily routine. It was something I had to do, otherwise, Id feel uncomfortable.

The result of Schoolings self-care experience isJS Orphic, a four-pronged skincare range made up of his daily grooming essentials: Pore Care Splash-Away cleanser, My Favourite Skin Hydrator, UV Shield + Skin Protector, and Stem Cell + Snail Waterfall Serum.

Quotes courtesy of CNA Lifestyle.

#2 Ellie Challis &Katie Shanahan Shortlisted for One-to-Watch Award

15-year-old British swimmerKatie Shanahan has been making a name for herself as of late, with the City of Glasgow swimmer reaping half of her nations gold medals at this years European Youth Olympic Festival in Baku, Azerbaijan.

For her efforts, as well as her future promise, teen Shanahan has been shortlisted out of approximately 1,000 candidates for the annual SportsAid One-to-Watch Award

Ive achieved so much over the last year, but the highlight has to be being nominated for awards like this one with SportsAid, said Shanahan of her nomination.

It was such an amazing opportunity to compete at the European Youth Olympic Festival. I didnt even expect to medal, let alone break any records, especially because it was such a high-level meet.

I was also lucky to race at Mare Nostrum in Barcelona, but I knew that one was going to be completely different. I was coming up against Olympians, Commonwealth, and European champions and I was so pleased to be almost as fast as some of the swimmers I have always looked up to.

As for Ellie Challis, she, too, has been nominated for the award, following a record-breaking 2019 in the pool. The 15-year-old busted out the SB2 class 50m breast World Record at the British Para Swimming International Meet in Glasgow.

Its lovely to be recognised for the One-to-Watch Award and for all my achievements. Its really nice and its that recognition at such a young age that makes it so special for me.

The winner of the One-to-Watch Award will be revealed at the charitys Celebrate the Next event on Tuesday, November 19th.

Quotes courtesy of Scottish Swimming.

#3 Cate Campbell Joins Melanoma Awareness Campaign

Olympic championCate Campbell averted a melanoma scare in November 2018 when the Aussie had a mole removed, only to find out it was indeed cancerous. Since then, C1 has been on the awareness train, helping fellow Australian citizens be more skin-conscious and educated when it comes to the effects of the sun.

Most recently, Campbell has been named as teh face of Melanoma Institute Australias Game On Mole campaign.

Says C1 of her ambassadorship, Im actually quite a private person, but I only went and got a skin check after running into someone who had their own melanoma story to tell.

If I hadnt met them on the off chance, would I have gone for that skin check?

Id like to think so, but I cant be sure and I may still be walking around with melanoma in my arm possibly heading into my bloodstream, which could have caused more complications than just a scar.

So I felt like I had an obligation to share my story and to be a part of the Game On Mole campaign.

If by sharing you can save one person, or if one person hears the story and goes and gets their skin checked, then I think that thats a win.

Quotes courtesy of Perth Now.

#4 Katie Ledecky Joins Team Visa

Worldwide Payment Technology Partner of the Olympic and Paralympic Games, Visa, announced its roster of athletes on Team Visa Tokyo 2020. The more than 70 athletes span 30 sports and represent 43 nations, the most in Team Visa history.

As one of the longest-standing partners of the Olympic and Paralympic Games, Visa looks forward to Tokyo 2020. Set to be the largest Games yet, Tokyo 2020 will feature 7,000 hours of broadcast programming and three billion minutes of streamed content, said Chris Curtin, chief brand and innovation marketing officer, Visa.

Our Team Visa Tokyo 2020 roster reflects The Games themselves: globally diverse, representative of new emerging sports and larger than ever. We are proud to reveal this years Team Visa roster and support these athletes as go for Gold in Tokyo.

Founded in 2000, Team Visa has championed nearly 500 athletes. Each has been selected based on athletic achievements, character and personal journey, and is representative of many of Visas brand values and priorities.

American Olympic icon Katie Ledecky has been named to the Visa roster, along with Adam Peaty of Great Britain, Florian Wellbrock of Germany, Daiya Seto and Kanako Watanabe of Japan, Dmitriy Baladin of Kazakhstan, Tatjana Schoenmaker of South Africa, Gregorio Paltrinieri of Italy, Daniel Dias of Brazil, Aurlie Rivard of Canada,Teresa Perales of Spain andYelyzaveta Mereshko of Ukraine.

Read the original here:
Beyond The Lane Lines: Schooling Launches Skincare, Ledecky Joins A New Team - SwimSwam

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

For Critical Insights On Keyword Market, Request For Customization Here @https://www.persistencemarketresearch.com/request-customization/11341

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

Go here to see the original:
Myelofibrosis Treatment Market To Witness an Outstanding Growth During 2016-2022 - Zebvo

Third Quarter Revenue Grew 34% Over the Prior Years Quarter and 25% Year to Date

Acquired BioPharma Business in Partnership with Ampersand

Diagnostic Test Volume Grew 16% for the Quarter and 22% Year to Date

Conference Call and Webcast Wednesday November 13, 2019 at 4:30 pm ET

PARSIPPANY, NJ, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (formerly Interpace Diagnostics Group, Inc.) (Nasdaq: IDXG), a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications, announced today that it has changed its name to Interpace Biosciences, Inc. to better reflect its new business model that combines its traditional esoteric molecular diagnostic business with its recent acquisition of the BioPharma business of Cancer Genetics (CGIX), now known as Interpace Pharma Solutions, that uses its proprietary test systems and platforms to support drug discovery and development valued by pharmaceutical and biotechnology companies. Interpace Biosciences will continue to trade on NASDAQ as IDXG.

Interpace Biosciences recognized $7.7 million in Net Revenue for the quarter and $20.0 million year to date. Our Diagnostics business had volume growth of 16% for the quarter and 22% year to date. Medicare and contracted reimbursement remained strong and continued to grow across both products.

On July 15, 2019 Interpace closed on the acquisition of the BioPharma business of Cancer Genetics and accordingly from that date forward the BioPharma business is being reported in the results of operations of Interpace Biosciences. Further, on October 16, 2019 Interpace Biosciences closed on the $13 million second tranche round of financing with Ampersand Capital Partners (Ampersand) and on October 24th we completed settlement with Cancer Genetics under the Net Working Capital Adjustment as planned. We are now moving forward together as one company!

Certainly part of our rationale in acquiring the BioPharma business was risk diversification of our customer base and revenue stream but more importantly it was to take advantage of the synergies between these two businesses as cancer therapeutics move toward earlier stage treatment, require customized services and obligate many therapeutic companies to match their targeted therapies with companion diagnostics. Today, Interpace Pharma Solutions is involved in over 225 clinical trials including approximately 47 immuno-oncology trials. Focusing on the Pharma Solutions business, contracts are growing and bookings have been recorded through September 30, 2019 worth over $18 million that are expected to be recognized over the next year or more. Our near-term growth plans are to add additional business development personnel in key unserved markets, expand our immuno-oncology franchise and accelerate global expansion as recently indicated by our partnership with Genecast in Bejing, China.

We think that the combination of the Interpace Diagnostics and Interpace Pharma Solutions businesses, now under the Interpace Biosciences umbrella, is a great platform to leverage our broad based and synergistic capabilities, and deliver consistent growth. The addition of Ampersand as a significant financial and strategic partner and investor in Interpace Biosciences we believe provides validation of our model and plans as well as the basis for supporting future synergistic growth. Interpace Biosciences has demonstrated its ability to not only acquire meaningful assets but to also cost effectively integrate assets while continuing to grow.

During the third quarter we continued to drive volume growth across our products and completed the acquisition of the BioPharma business of Cancer Genetics (CGIX). We are especially pleased to be partnering with Ampersand Capital Partners, one of the best known and most successful funds in the laboratory services space, said Jack Stover, President & CEO Of Interpace. The transition process is happening on schedule and our goal, as previously stated, is to reach adjusted EBITDA breakeven before the end of next year, Stover said.

THIRD QUARTER 2019 FINANCIAL PERFORMANCE

For the Third Quarter of 2019 as Compared to the Third Quarter of 2018

-- Net Revenue was $7.7 million which included revenues of both our Diagnostics and Pharma Solutions business for part of the quarter, an increase of 34%; -- Gross Profit was 37%, a decrease compared to 52% primarily due to the acquisition of the BioPharma business and the reduction in the estimate of amounts to be collected resulting from our transition to a new billing and collections contractor. -- Sales & marketing expenses increased $0.7 million to $2.8 million; -- G&A Expenses were $4.5 million as compared to $2.1 million again related principally to our BioPharma acquisition and certain non-cash charges; -- Acquisition-related costs were $0.8 million in the current quarter with no such costs in the prior year; -- Loss from Continuing Operations was $(7.3) million as compared to $(3.0) million; -- Net Loss per basic and diluted share was $(0.19) versus $(0.11); -- Adjusted EBITDA was $(4.2) million as compared to $(1.0) million; and -- Net cash used in operations for the quarter was $(4.8) million as compared to $(1.8) million.

For the Nine Months Ended September 30, 2019 as Compared to the Nine Months Ended September 30, 2018

-- Net Revenue increased to $20.0 million, a 25% improvement; -- Gross Profit decreased to 48% from 53%; -- Sales & Marketing expenses increased $2.0 million or 33%; -- G&A expenses were $9.8 million as compared to $6.0 million due principally to costs associated with the BioPharma acquisition; -- Acquisition-related costs were $2.4 million with no such costs in the comparable period for the prior year; -- Loss from Continuing Operations was $(16.0) million as compared to $(8.0) million; -- Net Loss per Share was $(0.43) as compared to $(0.29); -- Adjusted EBITDA was $(7.7) million as compared to $(3.4) million; and -- Net cash used in operations was $(12.6) million as compared to $(6.8) million.

Cash and cash equivalents were $2.4 million as of September 30, 2019 before the closing of the second tranche financing with Ampersand on October 16th, 2019. From the proceeds received from the second closing with Ampersand, approximately $3.75 million was used to repay the balance in the revolving credit line, $6.02 million was used to repay the note to Cancer Genetics and the balance was used for general corporate purposes including the integration of the BioPharma business. Further, on September 20, 2019, the Company entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc., as sales agent, pursuant to which the Company may, from time to time, issue and sell shares of its common stock with an aggregate offering price of up to $4.8 million.. To date, no shares have been sold under this Agreement.

Adjusted EBITDA (in the attached schedule), which we believe is a meaningful supplemental disclosure that may be indicative of how management and our Board of Directors evaluate Company performance, is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock based compensation, interest and taxes, and other non-cash expenses including asset impairment costs, non-recurring acquisition and transition expenses, loss on extinguishment of debt, goodwill impairment, change in fair value of contingent consideration and warrant liability.

RECENT BUSINESS HIGHLIGHTS

Secured Additional Financing via Ampersand Capital Partners and Acquisition of BioPharma Business

Closed on a $13 million Convertible Preferred Stock investment by Ampersand constituting the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with Interpaces July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX).

Reimbursement Expansion Announced

In September we announced that we contracted with 3 independent Blue Cross Blue Shield (BCBS) plans in the South and Southwest totaling nearly 5 million covered lives; -- Announced diagnostic contract agreement with BCBS plans of Michigan and California; -- Announced agreement with SelectHealth to provide ThyGeNEXT and ThyraMIR in Utah and Idaho to more than 850,000 members; and; -- Announced that THyGeNEXT and ThyraMIR are now covered by Independence Blue Cross for its nearly 2.5 million members in Philadelphia and Southeastern PA.

Clinical Validation Announcements

-- Announced the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT when used alone and in combination with ThyraMIR; -- Presented new data on the performance of ThyGeNEXT and ThyraMIR at the American Thyroid Assn Annual Meeting in October; -- Presented new data on the performance of PancraGEN at the American College of Gastroenterology in October; and -- Presented at the World Congress on Thyroid Cancer in Rome on detail outcomes of a study using our thyroid assays in combination with microRNA testing.

Other

-- Entered into a strategic partnership with Genecast to partner biopharma solutions in China; -- Interpace named one of the 50 Most Admired Companies of the Year by Silicon Review; and -- Entered into agreement with Predictive Oncology to evaluate diagnosis of thyroid cancer via AI-driven analyses.

UPDATED NET REVENUE GUIDANCE

Interpace is adjusting its 2019 annual Net Revenue guidance to between $28 and $32 million as we continue to transition the BioPharma business and prepare for our first full year together. Interpace Biosciences is also confirming top-line revenue guidance of $50 million for 2020.

CONFERENCE CALL INFORMATION Interpace will hold a conference call and Webcast on Wednesday, November 13, 2019, at 4:30 pm ET to discuss financial and operational results for the third quarter ended September 30, 2019. Details are as follow:

Date and Time:Wednesday, November 13, 2019 at 4:30 pm ET Dial-in Number (Domestic):(877) 407-0312 Dial-in Number (International):+1 (201) 389-0899 Confirmation Number:13690534 Webcast Access:https://webcasts.eqs.com/interpacedia20190513/en

The webcast replay will be available on the Companys website approximately two hours following completion of the call and archived on the Companys website for 90 days.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.

Interpace Pharma Solutions provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries and advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.For more information, please visit Interpaces current website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement, including that there is no assurance that the acquisition of the BioPharma business will be successfully integrated with the Company, that the potential benefits of the acquisition, including future revenues, will be successfully realized, that other potential acquisitions will be successfully consummated, that the Company will be able to maintain its Nasdaq listing and that the Company will be able to meet its revenue projections. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor Relations Edison Group Joseph Green (646) 653-7030 jgreen@edisongroup.com

Non-GAAP Financial Measures

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, Interpace Biosciences has provided certain non-GAAP financial measures to help evaluate the results of its performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing the Companys ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the Companys financial results in the way that management views financial results.

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, acquisition related expenses, transition expenses, non-cash stock based compensation, interest and taxes, and other non-cash expenses including asset impairment costs, bad debt expense, loss on extinguishment of debt, goodwill impairment and change in fair value of contingent consideration, and warrant liability. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share data)

Three Months Ended Nine Months Ended September 30, September 30, -------------------- --------------------- 2019 2018 2019 2018 -------- -------- --------- -------- Revenue, net $ 7,725 $ 5,753 $ 20,005 $ 16,062 Cost of revenue 4,835 2,763 10,489 7,590 - ------ - ------ - ------- - ------ Gross Profit 2,890 2,990 9,516 8,472 Sales and marketing 2,757 2,048 8,127 6,135 Research and development 857 510 2,032 1,528 General and administrative 4,492 2,084 9,790 5,981 Acquisition related expense 838 - 2,534 - Acquisition related amortization expense 995 813 2,621 2,439 Total operating expenses 9,939 5,455 25,104 16,083 Operating loss (7,049 ) (2,465 ) (15,588 ) (7,611 ) Accretion expense (111 ) (248 ) (331 ) (248 ) Other income (expense), net (135 ) (288 ) (12 ) (143 ) - ------ - ------ - ------- - ------ Loss from continuing operations before tax (7,295 ) (3,001 ) (15,931 ) (8,002 ) Provision for income taxes 9 7 19 21 - ------ - ------ - ------- - ------ Loss from continuing operations (7,304 ) (3,008 ) (15,950 ) (8,023 ) Loss from discontinued operations, net of tax (58 ) (34 ) (51 ) (129 ) Net loss $ (7,362 ) $ (3,042 ) $ (16,001 ) $ (8,152 ) - ------ - ------ - ------- - ------ Basic and diluted (loss) income per share of common stock: From continuing operations $ (0.19 ) $ (0.11 ) $ (0.43 ) $ (0.29 ) From discontinued operations (0.00 ) (0.00 ) (0.00 ) (0.00 ) - ------ - ------ - ------- - ------ Net (loss) income per diluted share of common stock $ (0.19 ) $ (0.11 ) $ (0.43 ) $ (0.29 ) - ------ - ------ - ------- - ------ Weighted average number of common shares and common share equivalents outstanding: Basic 38,196 28,215 37,169 28,002 Diluted 38,196 28,215 37,169 28,002

Selected Balance Sheet Data (Unaudited) ($ in thousands)

September December 30, 31, -------- -------- 2019 2018 -------- -------- Cash and cash equivalents $ 2,358 $ 6,068 Total current assets 20,581 17,721 Total current liabilities 17,296 8,492 Total assets 74,673 48,442 Total liabilities 37,915 15,504 Total preferred stock 13,161 - Total stockholders equity 23,597 32,938

Selected Cash Flow Data (Unaudited) ($ in thousands)

For the Nine Months Ended September 30, --------------------- 2019 2018 --------- -------- Net loss $ (16,001 ) $ (8,152 ) Net cash used in operations $ (12,556 ) $ (6,800 ) Net cash used in investing activities (13,921 ) (388 ) Net cash provided by (used in) financing activities 22,767 (9 ) - ------- - ------ Change in cash and cash equivalents (3,710 ) (7,197 ) Cash and equivalents, Beginning 6,068 15,199 Cash and equivalents, Ending $ 2,358 $ 8,002

GAAP to Non-GAAP Reconciliation (Unaudited) ($ in thousands) Quarters Ended Nine Months Ended September 30, September 30, ---------------------- ----------------------- 2019 2018 2019 2018 -- ----- - -- ----- - -- ------ - -- ----- - Loss from continuing operations (GAAP Basis) ($ 7,304 ) ($ 3,008 ) ($ 15,950 ) ($ 8,023 ) Acquisition related expense 838 - 2,534 - Transition expenses 836 - 836 - Depreciation and amortization 1,074 870 2,823 2,580 Stock-based compensation 211 525 1,247 1,564 Bad debt expense - - 499 - Taxes - 7 - 21 Accretion expense 111 248 331 248 Mark to market on warrant liability 10 325 -35 259 Adjusted EBITDA (Non-GAAP Basis) ($ 4,224 ) ($ 1,033 ) ($ 7,715 ) ($ 3,351 ) -- ----- - -- ----- - -- ------ - -- ----- -

Read more from the original source:
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results -...

NEW YORK, Nov. 13, 2019 /PRNewswire/ --

KEY FINDINGSThe global metabolomics market is predicted to showcase growth at a CAGR of 11.84% during the projected period. The surging chronic diseases, along with the prevalence of cancer, are the major factors influencing the growth of the global market of metabolomics.

Read the full report: https://www.reportlinker.com/p05826891/?utm_source=PRN

MARKET INSIGHTSThe report includes the segmentation on the basis of application, indication, and product & service.The use of metabolomics in studying cancer would be instrumental as it would result in new biomarkers for cancer, which are further used in the diagnosis of the disease.

Also, advancements in personalized medicine aids in a scientific understanding of diseases like cancer and genetic diseases.The development of methodologies has always been given preference when it comes to research activities in nutrition.

This is set to result in huge market growth opportunities in the global metabolomics market. The metabolomics incurs huge costs in terms of instrumentation, and this factor can limit the market growth.

REGIONAL INSIGHTSThe global market with regard to metabolomics is analyzed on the basis of North America, Europe, Asia Pacific, and the Rest of the World.The North American market region is projected to garner the largest market share by the end of the forecast period.

The region has a large presence of several end-users.The market region of Asia Pacific is estimated to record the highest CAGR for the metabolomics market.

The growth is attributed to the presence of economically diverse countries in the region.

COMPETITIVE INSIGHTSThe market has the presence of key players that aid in the growth and revenue of the market. Some of the key players include, Bruker Corporation, Danaher Corporation (Sciex), Bio-Rad Laboratories, Inc., Biocrates Life Sciences Ag, Creative Proteomics, Apical Scientific Sdn Bhd, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned1. AGILENT TECHNOLOGIES, INC.2. APICAL SCIENTIFIC SDN BHD3. BIOCRATES LIFE SCIENCES AG4. BIO-RAD LABORATORIES, INC.5. BRUKER CORPORATION6. CREATIVE PROTEOMICS7. DANAHER CORPORATION (SCIEX)8. HUMAN METABOLOME TECHNOLOGIES, INC.9. KORE TECHNOLOGY LIMITED10. LECO CORPORATION11. METABOLON INC.12. PERKINELMER, INC.13. SHIMADZU CORPORATION14. THERMO FISHER SCIENTIFIC INC.15. WATERS CORPORATION

Read the full report: https://www.reportlinker.com/p05826891/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the rest here:
The region has a large presence of several end-users.The market region of Asia Pacific is estimated to record the highest CAGR for the metabolomics...

ByKristin Hanson

This article was originally published on Nov. 8 on giving.jhu.edu

Between 2001 and the beginning of 2018, more than 1,500 U.S. military service members lost limbs in the line of duty. Although technology has improved the prosthetic devices these people can use, a stubborn obstacle remains: the fragility of human skin.

"Skin was never meant to hold this kind of pressure," says Lee Childers, the senior scientist for the Extremity Trauma and Amputation Center of Excellence at Brooke Army Medical Center in San Antonio, Texas.

"Think about it like a blister on your foot. It's painful, but you can still get by," he continues. "In an amputation, it's a blister on your residual limb. You can't use your prosthesis until the blister is completely healed. If it's your leg [that is affected], you can't walk for two or three weeks. Think about how that would impact your life."

What if there were a way to make the skin at an amputation site tougher, like the palm of your hand or the sole of your foot? Luis Garza, an associate professor of dermatology at Johns Hopkins and leader of the Veteran Amputee Skin Regeneration Program, is developing a cell therapy that could enable prosthetics wearers to use their devices longer.

"This is an example of personalized medicine," Garza says. "We're taking each person's own cells, growing them up, and inserting them back in."

Garza's postdoctoral research focused on skin stem cells. In 2009, he and his department chair, Sewon Kang, began having conversations about how that work could help the increasing numbers of veterans coming back from war with amputations. Garza and his team received grants from the U.S. Department of Defense, National Institutes of Health, and Maryland Stem Cell Fund that have moved the program forward in the past decade.

Garza's team spent the summer of 2019 testing "normal" subjectsthose without amputationsto perfect the procedure, including the dose, content, method, and frequency of the injections. During one appointment, members of Garza's team took biopsies of skin from a subject's scalp and sole. The cells went to a lab where they were grown under an FDA-approved protocol and passed through quality control tests.

In a second appointment, subjects completed a questionnaire and underwent baseline measurements of their skin's thickness and strength. Garza's team then injected a site on the subjects' skin with the stem cells grown from their cells in the lab.

Image caption: Luis Garza, associate professor of dermatology at Johns Hopkins, leads the Veteran Amputee Skin Regeneration Program.

"We're hoping that these stem cell populations will engraft in the new skin," Garza says.

The subjects returned to Hopkins several months later to go through the questionnaire and measurements once more, and Garza's team documented changes.

Confident in the results they gleaned from the normal subjects, Garza's team enrolled its first subject with an amputation in August. Moving from the normal population to the amputation-affected population quickly unearthed some aspects of the therapy Garza didn't anticipate.

"When we talked with him, he said 'I don't want to mess with my one remaining footdo you have to take skin from there?' And we said, 'Actually, no, we could do your palm,'" Garza says.

His team then tested the biopsy and growth of palm cells from subjects in the normal population. "We're moving away from having our product informed purely by biology to letting our therapy development be shaped by the user."

Although federal grants have supported much of the program's progress, private philanthropy has played a role, too. Corporations like Northrop Grumman, foundations like the Alliance for Veteran Support, and grateful patients with and without ties to the armed forces have contributed nearly $300,000. Those gifts have enabled the program to persevere through gaps between federal grants.

Private funds will be increasingly important as the project enters its next phase: extension to military medical centers around the country. Garza's team must prove that the safeguards to protect cells on their round-trip voyage from a test site to Hopkins are effective. They also must secure approval by local institutional review boards for clinical studies.

"Soldiers are used to getting orders, but you can't order someone to be part of a [medical] study," Garza says. "There are hard medical ethics questions around how to make this open to them but ensure they don't feel obligated. We've been working on that for a year, and we probably have another six months or so to go."

Childers stands ready for whenever the program's extension is a go. He will lead the study at Brooke Army Medical Center and feels motivated by the prospect of helping many of the veterans he works with every day.

"We do everything we can to serve those who serve us. This can enable people to return to duty and be redeployed if they choose," he says. "This is game-changing technology that will have an impact for our service members, but also others who live with amputation."

That population includes the hundreds of thousands of Americans who've undergone amputations for complications of diabetes, who must use a wheelchair, or who wear ankle or foot orthoses for help with walking, among others.

"Having the ability to transform skin anywhere you want to target on the body will have gigantic implications across the entire spectrum of our society in many ways," Childers says.

There's a lot of work to be done before such benefits reach the public, Garza cautions. With continued support from donors and the military community, though, he's optimistic about the program's future.

"The challenges are pretty big, but I think within five years, it could happen," he says. "That's the hope."

Disclaimer: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of the Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force and Department of Defense or the U.S. Government.

Here is the original post:
Serving those who serve - The Hub at Johns Hopkins

CHF 32 Million in Milestone Revenues

Multiple Upcoming Catalysts

Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline

LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today provided a business and clinical update and reported its consolidated financial results for the third quarter of 2019.

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune, commented: AC Immune, together with our leading pharmaceutical partners, is advancing one of the industrys broadest, most diversified development pipelines targeting neurodegenerative diseases. This quarter, we continued to demonstrate strong progress across our pipeline of potentially best-in-class small molecule, antibody, and vaccine therapeutics, as well as our cutting-edge diagnostic agents. This resulted in milestones achieved totaling CHF 32 million which were comprised of CHF 30 million from Eli Lilly and Company and EUR 2 million (CHF 2.2 million) from Life Molecular Imaging.

Prof. Pfeifer continued, We anticipate multiple catalysts in 2019 and 2020, highlighted by expected Phase 2 data for semorinemab, our anti-Tau antibody partnered with Genentech/Roche, which we anticipate will be the first Phase 2 data available for a Tau-targeted therapy in Alzheimers disease (AD). We also anticipate achieving further progress across our development pipeline with both early and late stage data readouts that we believe will build substantial value for the Company.

AC Immunes unique, multi-pronged approach is designed to address the full spectrum of neurodegenerative diseases. By selectively targeting misfolded pathological proteins both intracellularly and extracellularly, and by creating state-of-the-art diagnostic imaging agents that enable early detection of multiple disease pathologies and tracking of disease progression, AC Immune is pioneering a personalized medicine approach to deliver the right therapy to the right patient at the right time.

Research & Development Highlights

Analysis of Financial Statements for the Three and Nine Months Ended September 30, 2019

About AC ImmuneAC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTMand MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen Pharmaceuticals Inc.

As a strategic leader in the field of neurodegenerative diseases, AC Immune has developed a five-point Roadmap to Successful Therapies for Neurodegenerative Diseases that recognizes the importance of treating earlier, targeting Tau, focusing on more homogeneous patient populations, precision medicine and exploring neuroinflammation as a target.

For further information, please contact:

Forward-looking statementsThis press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions Item 3. Key InformationRisk Factors and Item 5. Operating and Financial Review and Prospects in AC Immunes Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Story continues

Balance Sheets

Statements of Income/(Loss)

Statements of Comprehensive Income/(Loss)

Reconciliation of Income/(Loss) to Adjusted Income/(Loss) and Earnings/(Loss) Per Share to Adjusted Earnings/(Loss) Per Share

(a) Reflects non-cash expenses associated with share-based compensation for equity awards issued to Directors, Management and employees of the Company. This expense reflects the awards fair value recognized for the portion of the equity award which is vesting over the period.

(b) Reflects foreign currency remeasurement gains and losses for the period, predominantly impacted by the change in the exchange rate between the US Dollar and the Swiss Franc.

(c) Effective interest expense for the period relates to the accretion of the Companys convertible loan in accordance with the effective interest method.

(d) Change in fair value of conversion feature that is bifurcated from the convertible loan host debt with Lilly.

For the three and nine months ended September 30, 2019, adjustments increased net income and decreased net income by CHF 0.6 million and CHF 0.9 million compared with decreases to the net losses by CHF 1.9 million and CHF 3.0 million for the comparable periods in 2018, respectively. The Company recorded CHF 0.9 million and CHF 2.0 million for the three and nine months, respectively, for share-based compensation expenses. There were foreign currency remeasurement gains of CHF 0.3 million and remeasurement losses of CHF 0.3 million, respectively, related to foreign currency fluctuations. The Company recorded nil and CHF 1.4 million for amortization of effective interest for the three and nine months ended September 30, 2019, respectively. Finally, the Company recognized nil and a CHF 4.5 million gain for the change in fair value of the liability related to the conversion feature.

Read more from the original source:
AC Immune Q3 2019 Financial Results and Business Update - Yahoo Finance

Personalized Medicine Market Overview:

The recent report added by Verified Market Research gives a detailed account of the drivers and restraints in the Personalized Medicine Market. The research report, titled [Personalized Medicine Market Size and Forecast to 2026] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the Personalized Medicine Market and the current trends that are likely to shape its future. Primary and secondary research methodologies have been used to put together an exhaustive report on the subject. Analysts have offered unbiased outlook on the Personalized Medicine Market to guide clients toward a well-informed business decision.

The comprehensive research report has used Porters five forces analysis and SWOT analysis to give the readers a fair idea of the direction the Personalized Medicine Market is expected to take. The Porters five forces analysis highlights the intensity of the competitive rivalry while the SWOT analysis focuses on explaining strengths, weaknesses, opportunities, and threats present in the Personalized Medicine Market. The research report gives an in-depth explanation of the trends and consumer behavior pattern that are likely to govern the evolution of the Personalized Medicine Market.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=MG24&utm_medium=AK

Key Players Mentioned in the Personalized Medicine Market Research Report:

Personalized Medicine Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the Personalized Medicine Market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the Personalized Medicine Market.

Personalized Medicine Market: Research Methodology

The research methodologies used by the analysts play an integral role in the way the publication has been collated. Analysts have used primary and secondary research methodologies to create a comprehensive analysis. For an accurate and precise analysis of the Personalized Medicine Market, analysts have bottom-up and top-down approaches.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=MG24&utm_medium=AK

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=MG24&utm_medium=AK

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. Our aim is to save your Time and Resources, providing you with the required Research Data, so you can only concentrate on Progress and Growth. Our Data includes research from various industries, along with all necessary statistics like Market Trends, or Forecasts from reliable sources.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email:sales@verifiedmarketresearch.com

Tag: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Analysis, Personalized Medicine Market Forecast, Personalized Medicine Market Outlook, Personalized Medicine Market Trends, Personalized Medicine Market Research, Personalized Medicine Market Report

Read the original post:
Personalized Medicine Market Size 2019 By Top Key Players, By Type and Application, Forecast to 2026 - Markets Gazette 24

Data Bridge Market Research Adds Gene Editing Tools Market Industry Trends and Forecast to 2026 new report to its research database. The report spread No of pages:350 No of Figures:60 No of Tables:220 in it.

This report proves to be a useful guide for the individuals related to Gene Editing Tools market as it accommodates data such as advancement patterns, competitive scene examination, and key locales improvement status. Few of the major competitors currently working in theThermo Fisher Scientific Inc.; CRISPR Therapeutics; Editas Medicine; National Human Genome Research Institute; Intellia Therapeutics, Inc.; Merck KGaA; Horizon Discovery Ltd.; GeneCopoeia, Inc.; ERS Genomics; Takara Bio Inc.; New England Biolabs; GenScript among others.

Get a Sample PDF of Gene Editing Tools Report @ (Note: Kindly use your business/corporate email id to get priority): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-editing-tools-market

Global Gene Editing Tools Market is expected to register a healthy CAGR of 17.63% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the growing preferences in demands for personalized medicine.

The examination is an ideal blend of both quantitative and qualitative data featuring key market augmentations, challenges that industry and rivalry are trying alongside segmentation and new opportunities accessible and pattern in the Gene Editing Tools Market.

Research strategies and tools used of Gene Editing Tools Market:

This Gene Editing Tools market research report helps the readers to know about the overall market scenario, strategy to further decide on this market project. It utilizes SWOT analysis, Porters Five Forces Analysis and PEST analysis.

Breakdown of Gene Editing Tools Market:

The Gene Editing Tools market report performs segmentation which is done on the basis of type, end-user, and manufacturers and applications to fully and deeply research and reveal market profile and prospects.

Understands the Latest Trend of Gene Editing Tools:

Global Gene Editing Tools Market By Product (CRISPR/Cas9, ZFNs, TALENs, Viral Systems, Transposon Systems, Others), Application (Veterinary Medicine, Cell Line Engineering, Bioremediation, Food & Brewing Development, Food Waste Management, Bio Sensing Development, Others), Disease Application (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimers Disease, Obesity, Others), End-User (Biotech & Pharma Companies, CROs, Academic & Research Institutes, Food Industry, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Regional Insights of Gene Editing Tools:

Regional analysis helps the market players to take an exhaustive assessment of the Gene Editing Tools market region wise so that it becomes easy for them to distinguish and investigate the developing pattern and hidden opportunities all over the world.

The Gene Editing Tools market covers regions such as- South America, North America, Europe, Asia-Pacific, Middle East, and Africa.

Chapter Details of Gene Editing Tools

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Gene Editing Tools Market Landscape

Part 04: Gene Editing Tools Market Sizing

Part 05: Gene Editing Tools Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-gene-editing-tools-market

What does this report offer? -:

Developing patterns alongside critical drivers, difficulties and conceivable outcomes.

Fortifies decision making capabilities of market players.

Statistics of the market in form of graphs, pictures, pie-charts and tables.

Detailed knowledge of Gene Editing Tools market.

Competitive Evaluation:

The Gene Editing Tools research report highlights the import market Dynamics of the Industry, Definitions and Software of this Series and Also business arrange of this Market. Future prospects of this industry and Market scenario. Also, Prime strategical tasks on the current Market including improvements, mergers, acquisitions and Partnership, etc.

Analysis of the Market with Analytical tools

The report additionally accompanies an investigation of the business focused scene combined with a profoundly nitty gritty SWOT examination also.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Go here to read the rest:
Gene Editing Tools Market Continuous Excellent Growth | Intellia Therapeutics, Inc.; Merck KGaA; Horizon Discovery - Eastlake Times

PRP, or platelet-rich plasma, is part of a revolution in medicine. PRP contains an abundance of growth factors that play a valuable role in healing many ailments. The PRP technology has been developing for the benefit of patients, resulting in improved outcome and great results.

Platelet-rich plasma has evolved over the past 15 years from an experimental treatment and an idea that concentrated platelets can heal injuries to an everyday treatment that benefits so many. Platelets are concentrated by taking your blood in a tube or syringe and spinning the blood in a high-speed centrifuge that causes the components of blood to separate, including the red blood cells, white blood cells and platelets. The first generation of platelets involved one or two spins to separate the platelets, often including an anticoagulant to prevent clotting and solidifying of the platelets so it can be spread as a liquid around the target. This PRP has been effective for a range of musculoskeletal conditions. The second generation of PRP involves formation of a platelet-rich fibrin matrix (PRFM) that is valuable as a gel that can be applied to wounds, surgical sites and for dental conditions.

The third generation of PRP, also called CGF or concentrated growth factors,

was first developed and described in 2006 by an Italian physician (Dr. Sacco) and has recently become widely available in the United States with the Medifuge centrifuge. With a single spin, the blood is spun at multiple speeds, which concentrates the platelets while also isolating cells that express CD34+. This is a type of stem cell that greatly enhances the effectiveness of the platelets. The other advantage of this third-generation PRP is that without anticoagulants the platelets can be applied quickly as a liquid to apply to injured tendons and ligaments or for cosmetic benefit. By waiting a few minutes the platelets solidify, which is great for applying to wounds. Even when applied as a liquid, the third generation platelets solidify soon after injected, which helps attach the platelets to the area injected. This allows the platelets to provide growth factors for a longer duration to increase effectiveness.

There are many applications for this advanced PRP. Ligament and tendon injuries respond very well to PRP. These injuries often do not heal spontaneously because the ligaments and tendons do not get good blood flow. With PRP and its accompanying growth factors, the tendon and ligament is able to finally heal, providing long-term relief. In contrast to a steroid injection, which provides short-term relief and may contribute to tissue degeneration, PRP helps build and strengthen tissue and provides long-term relief.

To clarify, tennis elbow, golfers elbow, rotator cuff tendonitis, wrist tendonitis, iliotibial band syndrome, Osgood-Schlatters and Achilles tendonitis are all examples of tendon injuries characterized by weakening of the tendon fibers or even partial tears. PRP strengthen the tendon and heals all of these conditions.

Ligament injuries include all joint sprains and strains such as ankle sprains, shoulder strains, etc. The hallmark of joint arthritis is weakening of the ligaments that leads to wear and tear of the joint, with a cascade of cartilage erosion that leads to bone spurs, then joint space narrowing and eventually bone on bone. Any time you see a bone spur, chances are that there is a loose ligament that created the conditions that led to that spur. Platelets heal the ligaments so that the joint is more stable and the arthritic pain is relieved and recurrent ankle sprains stop recurring.

Thus, PRP is very effective for arthritic joints, including knee arthritis, hip arthritis and shoulder arthritis among others. The PRP is effective at strengthening the joint capsule that is comprised of ligaments and can provide support for the joint cartilage. Even with severe bone-on-bone arthritis, PRP can help strengthen the ligaments around the joint, which helps reduce pain.

PRP can also help you improve your appearance. With the vampire facial you get the benefit of the healing growth factors, which lead to increased collagen and blood flow for skin rejuvenation. The great aspect of this treatment is that this is a very natural way to naturally enhance your skin. Without undergoing surgery you can achieve a youthful appearance. So while stars such as Bar Rafaeli and Kim Kardashian have used platelets to enhance their appearance, the vampire facial is accessible to you and will give your skin a healthy, revitalized feeling. Everyone has an inner beauty. PRP helps your outer beauty so it is in sync with your inner beauty.

There are other cosmetic benefits to platelets. The growth factors that the platelets release can heal scars. This includes unsightly scars after a surgery or a laceration. Growing collagen within the scar will usually improve its appearance. Acne scars, which are tiny holes along the skin surface, are filled in with platelets. Burn scars may not be totally eliminated with PRP, but the growth factors can have dramatic effects on the appearance of these scars.

Another cosmetic benefit of PRP is hair growth. PRP leads to increased hair follicle formation increasing the hair density. While not practical for total hair loss, PRP is excellent for treating thinning hair in men and women. The best part is that you are stimulating the follicle growth with your own platelets without the use of medications or other invasive procedures. So if you run your hand through your hair and you feel it is thinner than you would like, PRP may be for you.

PRP is abundant, safe and the worlds most sophisticated repair system. Nothing else comes close to its amazing properties. PRP is a powerful source of growth factors. Whats best is that it comes from your own body so you are healing your own body with your own platelets. Whether you have an injury that needs the healing benefit of platelets, or if you want to enhance your appearance, promote hair growth or improve a scar, or for other challenges that can be enhanced with platelets, you should consider PRP to improve your quality of life. The success of PRP has been enhanced with the new technology of third-generation PRP. The concentrated growth factors (CGF) optimize platelets that are enhanced by stem cells for maximal benefit.

Dr. Slaten is a pain wellness physician in Ridgewood. For more than 20 years he has been practicing regenerative techniques with great skill and an open mind. Check out his website at http://www.njprp.com for more information.

See the article here:
The Third Generation of PRP Is Here - Jewish Link of New Jersey

NEW YORK, Nov. 12, 2019 /PRNewswire/ -- The North America diabetes care devices market is expected to reach US$ 15,300.0 Mn in 2027 from US$ 8,936.5 Mn in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05794734/?utm_source=PRN

The growth of the diabetes care devices market is primarily attributed to the growing geriatric population and rapid technological advancements in diabetes care devices.However, high cost of diabetes care devices and risks associated with the insulin delivery devices are likely to pose a negative impact on the market growth.

On the other hand, development of cost efficient pen needles is likely to have a positive impact on the growth of the North America diabetes care devices market in the coming years.The advancement in the field of the healthcare industry is driving to the players for more research and developments for insulin delivery devices.There are many methods to deliver insulin into the body such as needles, insulin pens and insulin pumps.

Insulin pumps are small computerized diabetes management devises, connected with cannula under the skin that is used to deliver a slow continuous level of insulin.The program can be controlled by the individual depends on the more or less requirement.

The increasing advancements and technology in glucose monitoring devices have result into smaller required blood volumes with improved accuracy.The ability to transfer data between the blood glucose (BG) meter and insulin delivery devices has been also improved.

The increasing advancements in blood glucose (BG) monitoring technology have resulted in improved accuracy, smaller required blood volumes, and the ability to transfer data between the BG meter and insulin delivery devices. For instance, in September 2016, the FDA announced their first automatically automatic glucose monitoring device, Medtronic's MiniMed 670G which is a hybrid closed looped system that provide suitable insulin doses in patient of age 14 years and above with diabetes type 1. Pen needles and syringes are the most commonly used device for injecting insulin to the diabetic patients. In addition, to reduce the injection site repetition for drug administration, montmd Inc. in April 2017 introduced a new a variant of SiteSmart colored pen needles to keep the injection site tissue healthy and promote better insulin adoption. Thus, the technological advancements coupled with increasing influx of new products into the market is expected to propel the growth of global pen needles market over the forecast years.

In 2018, the glucose monitoring devices segment held a largest market share of 54.2% of the diabetes care devices market, by product. The glucose monitoring devices is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes and presence of the several market players that offers technically advanced products. The testing strips segment among the glucose monitoring devices is anticipated to witness the fastest growth rate of 7.2% during the forecast period, 2019 to 2027 owing to the enormous usages in the glucose monitoring devices.

Homecare held a largest market share of 59.9% of the diabetes care devices market, by end user in 2018. This segment is also expected to dominate the market in 2027 owing to the rise in the demand for the glucose monitoring devices and insulin delivery devices. Increasing diabetic population, the ease of use, availability, and accessibility of insulin delivery devices has also increased the adoption of self-administration among patients is anticipated to grow at a steady rate during the forecast period. Also the homecare segment is also expected to grow at the fastest growth rate of 6.6% during the forecast period, 2019 to 2027.

Some of the major primary and secondary sources for diabetes care devices included in the report are, Associao de Diabetes Juvenil (ADJ), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), International Diabetes Federation(IDF) National Institute for Health and Care Excellence (NICE) and others.

Read the full report: https://www.reportlinker.com/p05794734/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Excerpt from:
The North America diabetes care devices market is expected to reach US$ 15,300.0 Mn in 2027 from US$ 8,936.5 Mn in 2018 - PRNewswire

There are 425 million diabetic people in the world and by 2045, that number is estimated to swell to 629 million. Image Credit:

As cheerless as it may sound, it is a fact that is diabetes is not just an individuals problem to tackle but the entire familys concern and the International Diabetes Federation has done well to theme this years World Diabetes Day on Family and Diabetes.

The overwhelming global concern for this disease, year after year, is not only warranted, it needs to be scaled to the highest levels of awareness because this is a health affliction that, rampant as it is, is predicted to get worse. Currently, there are 425 million diabetic people in the world and by 2045, that number is estimated to swell to 629 million, according to the Interactional Diabetes Federation (IDF).

The implications of such numbers are staggering in their import not just for individuals and families but also for governments who need to bear the cost of combating diabetes in their health care systems.

The discussions and urgencies about diabetes occupy two main streams: prevention and management, and both get equal play in the spotlight but there is, inarguably, a greater case to be made for the former.

The preventative aspect of diabetes is incalculable for the positive results it brings, by striking at the very root of the epidemic.

Experts stress on how important it is to continually maintain an environment of education, resources and implementation to help people stay informed on how diabetes can prevented, or having been diagnosed, be managed. But herein lies the rub. According to IDF, in 2013, of the 371 million people diagnosed with diabetes, nearly half of them did not know they had the condition.

This is precisely why this years theme is so powerful. Its not just the individual who needs to be aware of diabetes; families too need to stay educated on the genetic history of the disease, a hugely significant factor, and be focused on the importance of diet, exercise and stress management as pre-emptive factors because when diabetes strikes one or more members of a family, the lifestyle adaptations and discipline required to combat it are not individual responsibilities but a collective onus.

In the UAE, fortunately, there is much to be optimistic about. According to the National Health Survey in 2018, diabetes rates dropped to 11.8 per cent of the total population in 2017 from an alarming 19.3 per cent in 2013.

Let us all do our bit to keep this drop rate going.

View post:
This World Diabetes Day, family is the focus - Gulf News

The market is estimated to grow with a CAGR of 5. 7% from 2019-2027. The growth of the diabetes care devices market is primarily attributed to the rising incidence of diabetes and rising adoption of insulin injection pens over traditional syringes & vials.

New York, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Diabetes Care Devices Market to 2027 - Regional Analysis and Forecasts by Product; End User; and Country" - https://www.reportlinker.com/p05794715/?utm_source=GNW However, availability of alternatives for drug delivery and reuse of pen needles are likely to pose a negative impact on the market growth.

On the other hand, increasing launch of GLP-1 analogues is likely to have a positive impact on the growth of the Europe diabetes care devices market in the coming years.Glucagon like Peptide-1 also known as GLP-1 is a hormone produced in the gut that is released in response to the food consumed by an individual.The peptide reduces the appetite of an individual and helps to secrete insulin in the body among obese patients.

In recent years, external injection of GLP-1 has been witnessing a significant traction due to increase in the number of doctor prescription for these hormones. The rising number of novel GLP-1 analogue launches is thus expected to indirectly provide opportunities for the manufacturers to develop therapy specific pen needles with incorporation of features such as bore size, length and material that is not reactive with the biologic.In 2018, the glucose monitoring devices segment held a largest market share of 53.9% of the diabetes care devices market, by product. The glucose monitoring devices is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes and presence of the several market players that offers technically advanced products. The testing strips segment among the glucose monitoring devices is anticipated to witness the fastest growth rate of 6.6% during the forecast period, 2019 to 2027 owing to the enormous usages in the glucose monitoring devices.In 2018, the homecare held a largest market share of 59.8% of the diabetes care devices market, by end user. This segment is also expected to dominate the market in 2027 owing to the rise in the demand for the glucose monitoring devices and insulin delivery devices. Increasing diabetic population, the ease of use, availability, and accessibility of insulin delivery devices has also increased the adoption of self-administration among patients is anticipated to grow at a steady rate during the forecast period. Also the homecare segment is also expected to grow at the fastest growth rate of 5.9% during the forecast period, 2019 to 2027.Some of the major primary and secondary sources for diabetes care devices included in the report are, Centers for Diabetes and Endocrinology (CDE), Public Health England (PHE), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), International Diabetes Federation (IDF) and others.Read the full report: https://www.reportlinker.com/p05794715/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
The Europe diabetes care devices market is expected to reach US$ 11,184.6 Mn in 2027 from US$ 6,853.3 Mn in 2018 - Yahoo Finance

One helpful to distinguish between low and high carbs is to look at the glycemic index, or GI, which measures how a carbohydrate-containing food raises blood glucose.

A food with a high GI raises blood glucose more than a food with a medium or low GI.

According to the American Diabetes Association, meal planning with the GI involves choosing foods that have a low or medium GI so if you are eating a food with a high GI, you can combine it with low GI foods to help balance the meal.

According to Diabetes UK, to stay on the safe side, opt for foods that are high in fibre and whole grains instead of refined carbs, such white bread.

Fibrous foods packed with wholegrain are better for your heart health and reducing our risk of certain types of cancers, notes the health site.

Read more here:
Type 2 diabetes: Add this herb to your meals to lower blood sugar - Express

In recognition of National Diabetes Awareness Month, Morris Hospital & Healthcare Centers is offering a free diabetes awareness event on Monday, Nov. 18, from 9 a.m. to noon at the Channahon Healthcare Center of Morris Hospital, 25259 Reed St., Channahon. The event is for anyone interested in getting screened for diabetes, as well as those who have already been diagnosed.

Free blood glucose screenings, hemoglobin A1C blood testing and retinal scans will be provided, along with diabetes education and an opportunity to meet and talk with Morris Hospitals endocrinology providers, Dr. Nuzhat Chalisa and Jennifer Greggain, N.P. Reservations for testing can be made by calling 815-467-0555, but walk-ins are also welcome.

The blood glucose screening is a finger-stick test that provides instant results indicating whether a person has diabetes or pre-diabetes, meaning the blood sugar level is higher than normal but not high enough to be classified as Type 2 diabetes. A 12-14 hour fast is recommended prior to the screening for accurate results.

The hemoglobin A1C (HbA1c) test is a simple blood test is being sponsored by the Morris Lions Club and measures a persons average blood sugar levels over the past three months, specifically identifying the amount of glucose attached to hemoglobin. This is a common test used to diagnose prediabetes and diabetes and is also used to measure how a person is managing their condition.

Trained nurses will conduct retinal scans to test for diabetic retinopathy, an eye condition that results in damage to the blood vessels of the retina due to diabetes. The scans taken at the event will then be sent to Ortiz Eye & Hearing Associates where they will be reviewed free of charge.

Diabetes is a chronic condition that affects the way the body metabolizes sugar. According to American Diabetes Association, in 2015, 30.3 million, or 9.4 percent of the American population had diabetes. Of those, 7.2 million were undiagnosed. While there is no cure for diabetes, proper management of the condition can often help avoid serious health complications including heart disease, blindness, kidney failure, and lower-extremity amputations.

As endocrinology providers, Dr. Chalisa and Jennifer Greggain specialize in diagnosing and treating individuals who have pre-diabetic and diabetic conditions. If you have any questions or concerns about diabetes or pre-diabetes, or if you would like to schedule an appointment, please call 815-467-0555 or visit http://www.morrishospital.org/endocrinology.

More here:
Morris Hospital hosting diabetes awareness event this month in Channahon - Morris Daily Herald

SOMETIME NEXT year, if all goes to plan, a gay male couple in California will have a child. The child in question will have been conceived by in vitro fertilisation. In this case a group of eggs from a female donor are now being fertilised by sperm from both fathers (half from one, half from the other). Of the resulting embryos, the couple will choose one to be implanted in a surrogate mother. An uplifting tale of the times, then, but hardly a newsworthy event. Except that it is.

Where the story becomes newsworthy is around the word choose. For the parents, in conjunction with a firm called Genomic Prediction, will pick the lucky embryo based on a genetically estimated risk of disease. Such pre-implantation testing is already used in some places, in cases where there is a chance of parents passing on a condition, such as Tay-Sachs disease, that is caused by a single faulty gene. Genomic Prediction is, however, offering something more wide-ranging. It is screening embryos for almost 1m single-nucleotide polymorphisms (SNPs). These are places where individual genomes routinely differ from one another at the level of an individual genetic letter. Individual SNP differences between people rarely have much effect. But add them up and they can raise or lower by quite a lot the likelihood of someone suffering a particular disease. Generate several embryos and SNP-test them, then, and you can pick out those that you think will grow up to be the healthiest.

Upgrade your inbox and get our Daily Dispatch and Editor's Picks.

Much fuss was made last year about a researcher in China, He Jiankui, who edited the genomes of two human embryos in order to try, he claimed, to make them immune to infection by HIV, the virus that causes AIDS. What Genomic Prediction proposes is different. No editing is involved. There is thus no risk of harming a child by putting it through a risky experimental procedure. Whether Genomic Predictions particular technique will actually deliver super-healthy children remains to be seen. The principle seems plausible, though. History may therefore look back on this moment as the true beginning of designer babies. And the tool that has made that possible is called GWAS.

GWAS stands for genome-wide association study. It is the endpoint of a historical process that began in the mid-19th century with Gregor Mendel, a Moravian abbot and amateur botanist. Mendel worked out the first set of rules of heredity. This led to the idea of a gene. And that, when allied with the discovery that the material of heredity is a chemical called DNA, which encodes genetic information in the order of its component units, known as nucleotides, led to the idea of a gene being a particular piece of DNA that carries in its nucleotides the blueprint of a particular protein. This protein goes on to contribute, in combination with environmental effects such as nutrition, to a particular bodily or behavioural characteristic, known as a phenotypic trait.

Since the 1950s, researchers have tried to quantify the relative contributions of genes and the environment to such traits. Mostly, this is in the context of disease. But behavioural characteristics, personality and cognitive ability have also been matters of interest. GWAs expands this process by looking not just at the effects of individual genes, but across the whole genomefor protein-coding genes make up only about 2% of a persons DNA.

Comparisons, over several generations of a family, of the prevalence of a particular trait yield estimates of its heritabilitya measure of how well individual genetic differences account for variations in that trait in a given population. A heritability of 100% indicates that any differences in a trait between individuals in that population are accounted for solely by genetic factors, while 0% suggests the environment alone is responsible. The phrase given population is important. Some populations may be exposed to relevant environmental variables unknown to others. Conversely, genetic factors present in one group (better response to oxygen scarcity in those evolved to live at high altitude, for example) may be absent in another.

An analysis published in 2015 of more than 2,700 studies of heritability shows that its average value, for all traits looked into in those studies, is about 50%. That includes physical traits like susceptibility to heart disease (44%) and eye disorders (71%), and mental ones, including higher-level cognitive functions (47%) such as problem-solving and abstract thought.

Other, less obvious traits are heritable, too. The amount of time a child spends watching television was assumed for many years to have a heritability close to zero. In 1990, however, a study led by Robert Plomin, now at Kings College, London, compared the habits of adopted children with those of their birth mothers. It found television-watching has a heritability of about 45%. Similar surprisingly heritable traits include a childs tendency to be bullied at school (more than 70%) or to be accident-prone (51%). Even someones likelihood of being religious (30-40%) or of getting divorced (13%) is heritable.

In 1989 James Watson, the first head of the Human Genome Project, summarised the mood of many by declaring that We used to think our fate was in our stars. Now we know, in large measure, our fate is in our genes. There was hope then that the genome project would locate those genes. No one was naive enough to think that there existed, say, such a thing as a gene for television-watching. But it was reasonable to believe that there might be a handful of genes which combined to encourage television-watching indirectly. More important, there was an expectation that the heritable causes of things like heart disease might be pinned down to such genetic handfuls. These might then be investigated as drug targets. To everyones frustration, though, few such genes revealed themselves. And in most cases the contributions they made to a conditions heritability were small. Where, then, was the missing heritability?

With hindsight, the answer was obvious. The number of variants that play a role in disease risk is far higher than Mendel-blinded researchers had imagined. Though human beings are genetically more than 99.9% alike, they have 6bn genetic letters in their genomes. This is where the SNPs are hidden, for a diversity of less than 0.1% still leaves room for millions of them. And when SNPs contributions are combined, their effects can be significant. For height, for example, the number of relevant SNPs is reckoned to be about 100,000each adding or subtracting, on average, 0.14mm to or from a persons adult stature. Furthermore, most of these SNPs are in parts of the genome that do not encode proteins at all. Rather, they regulate the activities of other genes and often have no obvious connection to the trait in question.

To be fair, it was mainly human geneticists who were captivated by the simple Mendelian model of single genes with big effects. According to Peter Visscher of the University of Queensland, Australia, many plant and animal scientists knew of traits genetic complexity long before the Human Genome Project started. But they were more interested in breeding better crops or livestock than in understanding the biology behind such complexity.

Dr Visscher was one of the first to realise that human studies would need to recruit more participants and screen for many thousands more SNPs if they were to capture in full the genetic components of most traits. In 2007 he and his colleagues used models to show that for a condition with a prevalence of 10% in the general population, approximately 10,000 volunteers are required to identify the SNPs marking the 5% of those at highest risk of developing that condition. Earlier studies, often with just a few hundred participants, had simply not been powerful enough to see what was going on. And thus was GWAS born.

Ideally, a GWAS would obtain a full sequence of the genome of every participating individual. However, even though the cost of such sequences has fallen dramatically since the completion of the genome project, to about $1,000 a shot, this would still be prohibitively expensive. Instead, researchers use devices called SNP arrays. These detect hundreds of thousands of the most common SNPs for a price of $50 or so.

A combination of SNP arrays, larger samples of volunteers and better computing methods means it is now possible to find millions of variants that contribute to a trait. An individuals score from these variants, known as his polygenic score, can then be calculated by adding up their contributions to give, for example, his risk of developing a particular disease in later life.

Another advance has been a change in the way volunteers are recruited. Institutions called biobanks have come into existence. These hold both tissue samples from, and a range of medical and other data about, large numbers of people who have agreed to make those data available to researchers who meet the criteria employed by the bank in question.

Among the largest of these repositories is the UK Biobank, in Britain. This has 500,000 depositors. One study that drew on it, published in 2018 by Sekar Kathiresan of the Massachusetts General Hospital in Boston and his colleagues, worked out polygenic risk scores for five diseases, including coronary heart disease and type 2 diabetes. By totting up scores from over 6m genetic variants, they were able to elucidate SNP patterns that identify those who are at a threefold higher risk or worse than the general British population of developing one of these diseases. For heart disease, 8% of the population are at such risk. For type 2 diabetes, 3.5%.

Nasim Mavaddat of the University of Cambridge and her colleagues have similarly calculated polygenic risk scores for breast cancer. These showed that a British womans average ten-year risk of developing breast cancer at the age of 47 (the earliest that Englands National Health Service begins screening for the disease) is 2.6%. The study also found that the 19% of women who had the highest risk scores reached this level of risk by the age of 40. Conversely, the 10% at lowest risk did not cross the threshold until they were 80.

Using these and similar studies, it is possible to draw up lifetime risk profiles for various medical conditions. A British firm called Genomics has done that for 16 diseases (see chart). This will help screening programmes to triage who they screen, by offering their services earlier to those at high risk of developing a condition early in their lives. It will also permit the dispensing of risk-appropriate advice about diet and exercise to those who need it most, and the early offering to those who might benefit from them of things like statins and antihypertensive drugs. In light of all this Englands National Health Service announced in July that 5m healthy Britons would be offered free gene tests.

A third study that drew on the UK Biobank is rather different. It was published in October and demonstrated the power of GWAS to reach beyond non-medical matters. It examined patterns of internal migration in Britain, and showed that there has been an outward migration from former coalmining areas of people with SNP patterns associated with high educational attainmentprecisely the sorts of individuals economically deprived places can least afford to lose.

Educational attainment also demonstrates how heritability varies with environment. In Norway, for example, heritability of educational attainment increased after the second world war as access to education widened. Since all children now had more or less the same opportunities at school, environmental variation was largely ironed out and the effects of genetic differences consequently exaggerated.

Both of these examples foreshadow how the sort of genetics made possible by GWAS can have political consequences. The implication of the internal-migration study is that the geographically left-behind are dimmer, on average, than the leavers. The implication of the Norwegian study might likewise be seen by some as suggesting that those who have done well at school and thus snagged the best (and best-paid) jobs are part of a genetic elite that deserves its success, rather than being the lucky winners of a genetic lottery.

And that is just within a country. Start comparing people from different parts of the world and you enter a real minefield. Because most of the genetic data now available come from populations of European ancestry, their predictive power is poorer for people from elsewhere. Alicia Martin of the Broad Institute in Massachusetts and her colleagues scored West Africans for height based on SNPs drawn from studies on European or European-derived populations. The scores predicted that West Africans should be shorter than Europeans. Actually, they are not.

As more people of non-European ancestry are sequenced, these problems may abate. But if group-based differences emerge or persist in the face of better data, that would be cause for concern. Differences between groups in things like height are rarely cause for prejudice beyond a jocular level. For something like educational attainment, by contrast, there is a risk that politically motivated groups would try to exploit any differences found to support dubious theories of racial superiority.

To some historians, this looks horribly familiar. They fear that the old spectre of eugenics risks rising in a new guise. As Nathaniel Comfort of Johns Hopkins University, in Baltimore, observes, The IQ test was invented in order to identify students who needed extra help in school. But within about a decade, it was being used as a tool to weed out the so-called feebleminded, not just from school but from the gene pool. Such fears of genetic stratification would become particularly acute if polygenic scores were applied to embryos for the purpose of selecting which to implant during IVFas Genomic Prediction is just about to do.

Genomic Prediction and a second firm, MyOme (which is not yet accepting customers), claim to be able to build up an accurate picture of an embryos genome. That is tricky because the sequencing has to be carried out using the tiny quantities of DNA in a few cells taken from that embryo. A sequence so obtained would normally be full of errors. The two companies say they can deal with this by comparing embryonic sequences with those of the biological parents. All of the DNA in the embryo has come from one or other parent, so blocks of embryonic DNA can be matched to well-established sequences from their parental progenitors and an accurate embryonic sequence established. That makes working out the embryos SNP pattern possible.

Genomic Prediction thus says it is able to offer couples undergoing IVF a polygenic risk score for each embryo for a variety of diseases including type 1 diabetes, type 2 diabetes, breast cancer, testicular cancer, prostate cancer, basal-cell carcinoma, malignant melanoma, heart attack, atrial fibrillation, coronary artery disease, hypertension and high cholesterol. At the moment it does not offer scores for non-medical traits like height or educational attainment. But there is nothing to prevent it from doing so should it so wish.

Even for medically relevant scores, however, some worry about this approach. One concern is pleiotropythe phenomenon of the same piece of DNA influencing several apparently unrelated traits. Choosing an embryo with a low risk of heart disease might accidentally give it, say, a higher chance of developing epilepsy. Single-mindedly maximising scores for positive traits like intelligence or height may therefore increase the risk of genetic disorders.

Stephen Hsu of Michigan State University, one of Genomic Predictions founders, acknowledges the theoretical risk of this, but argues that serious pleiotropic effects are unlikely. If you looked at a bunch of kids with IQs of, say, 160 or 170, he says, I doubt youd find much seriously wrong with them. Theyd just be a bunch of geeks. Dr Hsu, who in 2014 predicted that reproductive technologies would soon be used to select for more intelligent offspring, estimates that an IQ gain of between 10 and 15 points would be possible if couples were allowed to choose between ten embryos. He also thinks that further gains would probably accumulate if people selected in this way went on to select their own offspring on the basis of intelligence.

This is plausible. Before 2008, when the first SNP chips for cattle became available, the annual milk yield of dairy cows in America had been increasing at about 50kg per year. After six years of chip-based polygenic selection, the rate of increase had doubled to more than 100kg per year. This suggests the technique is powerfulin cattle at least. Despite Dr Hsus optimism, however, pleiotropism has reared its head in these animals. They have become less fertile and have weaker immune systems.

In the end, then, it is generally a good idea to remember that human beings have already been optimised by a powerful agent called natural selection. Trade-offs between different pieces of physiology, even in domestic animals, will have been forged in the crucible of evolution and will generally be optimal, or close to it. Genetic tinkering may sometimes improve things. But by no means always.

Read more:
Modern genetics will improve health and usher in designer children - The Economist

LOS ALTOS, Calif. & FAIRFIELD, Calif.--(BUSINESS WIRE)--GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, announced today that NorthBay Healthcare, an independent nonprofit health system in Northern California, has selected the GenomeBrain Platform for a pilot program planned to improve the routine use of genetic testing in patient care.

Weve looked at many options to support our providers but the GenomeBrain Platform offered us more of the critical features we wanted plus gave us the ability to customize to our needs, said Lori Muir, Oncology Services Director. NorthBay Healthcare is dedicated to delivering best-in-class oncology care to the patients we serve and we believe ensuring easy access to genetic testing is a critical part of those vital services. Were looking forward to working with GenomeSmart to support our providers in better identifying patients for testing, efficiently tracking available tests, and speeding access to hereditary risk results.

"This approach to screening patients will make it much easier for people to understand why and when genetic testing can impact their healthcare decisions. We are bridging an educational gap that, until now, has made access to genetic testing difficult. Our patients will no longer wonder if genetic testing is right for themthey will know before they even come in to see me," added Karen Vikstrom, MS, Certified Genetic Counselor, NorthBay Healthcare.

The NorthBay Healthcare pilot program will be completed in conjunction with the NorthBay Breast Cancer Program. The pilot is designed to ensure patients with breast cancer receive treatment based on genetic risk and to scale testing into routine care for healthy women and men to identify potential hereditary risks, ensuring appropriate access to screening and care programs. The GenomeBrain Platform will be incorporated into the current patient workflow and evaluated for effectiveness and ease of use.

The GenomeBrain Platform is accessed online through a mobile phone, tablet, or desktop device. The simplified experience first builds a patient profile, including their relevant personal medical history, family medical history, ethnicity and age, and then instantly matches them to the appropriate genetic tests based on the latest medical guidelines for genetic testing. GenomeBrain uses AI to ingest large amounts of data from patient history, genetic tests available on the market, and medical guidelines to simplify a cumbersome manual process that usually takes days to less than ten minutes on average.

Were thrilled to be partnering with NorthBay Healthcare on this important initiative, said Sanjay Sathe, CEO and co-founder, GenomeSmart. The NorthBay teams agility and interest in innovative approaches to care make them the ideal partner for us. They are able to implement efforts quickly and provide personalized care to their local community that rivals many larger urban-based institutions, all for the betterment of their patients.

About GenomeSmart

GenomeSmart is on a mission to make genetic testing available to everyone. In May 2019, the company launched GenomeBrain, the first and only AI-powered genetic risk assessment and test recommendation platform that matches and identifies people who could benefit from genetic testing. The affordable GenomeBrain Platform multi-functional solution is available to help genetic counselors, physicians, hospital systems, genetic testing labs, insurance companies, and corporations improve the effective use of genetic testing to save lives, improve quality and reduce costs of healthcare.

About NorthBay Healthcare

NorthBay Healthcare opened its first hospital in 1960 and remains Solano Countys only locally based, locally managed nonprofit health system. NorthBay Medical Center in Fairfield and NorthBay VacaValley Hospital in Vacaville offer 24-hour emergency care, intensive care, and sophisticated surgical and diagnostic services. NorthBay Cancer Center, located on the Vacaville campus, opened more than 30 years ago. NorthBay Healthcare is a member of the Mayo Clinic Care Network, giving its patients access to world-renowned physicians and Mayo Clinic research.

See more here:
GenomeSmart and NorthBay Healthcare Launch Pilot to Improve Access to Genetic Testing with GenomeBrain - Business Wire

NFM Secret Shopper: Im confused about whats best to boost my immunity. Is it zinc, vitamin C, vitamin D, elderberry or something else?

Retailer: Any of those can help with immunity, but it depends on when you take them. Vitamin C is good for when you already have a cold, but if you eat your fruits and veggies, you probably dont need to take a vitamin C supplement all the time. Same with zinc and elderberry. But vitamin D is a supplement you might need every day, depending on your levels.

NFM: That makes sense. Any other supplements youd recommend, especially for cold and flu season?

Retailer: Garlic is popular and seems to work pretty well for immunity.

Our expert educator: Yufang Lin, M.D., of the Cleveland Clinics Center for Integrative and Lifestyle Medicine

Immunity is very complex. As an integrative practitioner, I look at the whole picture, so the first things I suggest are getting enough sleep, hydrating well and eating healthy. As for specific foods that boost immunity, garlic and ginger are both antimicrobial, antifungal and antiviral. You can use them in your day-to-day cooking, but if you are getting sick, definitely step up your intake, whether through food or supplements. Ginger, which is also anti-inflammatory, can also be made into tea.

There is data showing that both vitamin C and zinc support the immune system when you are sick. They are particularly useful in the first few days of illness, as they can reduce the duration and severity. But use these supplements only as needed, not on a long-term basis.

Elderberry is a diuretic, so if you are running a fever, it can help you sweat it out. Another supplement, echinacea, revs up the immune system, so it is great for fighting off a cold or even for the early stages of the flu. The problem with echinacea is it can stimulate the immune system too much, which is bad if you have an autoimmune disease. But for most people, it can be very helpful, but take it only for three to five days.

Vitamin D is a hormone so it generally has many benefitsfor mood, bone health and immune support. But it is more for day-to-day care, not to start taking once you get sick.

Read the original here:
Secret Shopper: What supplements are best to boost immunity? - New Hope Network

Tis the season for turkey trots, Black Friday sales and fighting over the last piece of pumpkin pie. Oh, and the flu.

According to the U.S. Centers for Disease Control and Prevention, 3% to 11% of people in the U.S. have to deal with the flu each year, with an average of 8% getting sick. And while the flu vaccine is a must, it still only reduces your flu risk by 40% to 60%, meaning its not a complete safeguard depending on your health, age and the type of flu virus you contract. (If you do contract the flu after youve gotten a flu shot, the vaccine will lessen the severity of symptoms and help prevent against flu-related complications like pneumonia. So its still important to get it.)

Here, flu experts share what happens once youre exposed to the flu including why it triggers some of those unpleasant symptoms like fevers, aches and chills. Read on to learn, plus get some guidance on how to stay as protected as possible this flu season.

First, the flu has to find a way to get into your body

Simply being in the house with someone who has the flu wont get you sick, but it can definitely increase your risk factor if youre not practicing proper hand-washing hygiene.

The virus has to find a way to get into either your nose or mouth, said Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. Its usually transmitted from person to person through coughing, sneezing, or mucus or saliva that might be on someones hands. It can also be transmitted from common surfaces that people may touch. They may have wiped their nose and then touched their hands before putting it on a surface or may have sneezed on the surface.

Your eyes and ears may be access sites as well, but Adalja said these are far less common entry points, so make sure you wash your hands often and well during flu season to prevent the virus from infecting you to begin with.

You wont have symptoms right away once the virus enters your system

Once the virus enters your nose or mouth through direct contact (like being sneezed on, yuck) or indirect (such as using a towel shortly after an infected person has previously used it) the virus will make its way to your immune system, but this wont happen immediately.

Once the flu gets into your body, it will set up shop and cause the same infection in you, said Aaron Glatt, chairman of infectious diseases and hospital epidemiologist at Mount Sinai South Nassau in Hewlett, New York. The incubation period is about one to four days. On average two days, but it is still a highly contagious disease during this time.

This means that you could be asymptomatic for a day or two but very much able to spread the flu to others without even knowing it.

torwai via Getty Images

Once the flu settles in, its heading for your cells

Specifically, the virus goes to your respiratory epithelial cells, which line your respiratory tract.

The virus binds to sialic acids that are on these cells, and these sialic acids function as receptors to help the cells signal and communicate to each other, Adalja explained.

The virus is able to bind to these cells thanks to a protein called hemagglutinin (which is what the H stands for in flu strains like H1N1). With the help of this protein, the virus attaches itself to the cell and then gets inside the cell, which will send an alarm to your immune system.

Some flu symptoms are from an immune system response

After your immune system figures out theres a virus inside the body, it will go into overdrive to get it out as quickly as possible.

As part of that, the immune response will start to ramp up some of the symptoms that you feel. Fevers, muscle aches and pains are the result of certain chemicals being secreted by the immune system in order to fight that virus off, Adalja said, adding that a quarter of people with the flu have no symptoms. This doesnt mean your immune system isnt working, its just how you clinically present the virus.

Basically, your body becomes a battlefield when you have the flu and the reason you feel so terrible is from the war between the pathogen and your immune system, Adalja said.

Prostock-Studio via Getty Images

The average shelf life of the virus is about a week

Most healthy people have self-limited disease, Glatt said. They get sick for a couple days, or some people dont get very sick at all. Other people get a mild illness or more moderate illness for a couple of days or a week or two at most.

The standard run-of-the-mill flu in a healthy person typically doesnt require treatment but certain groups are at a higher risk of developing complications from the flu including pregnant women, those with certain underlying diseases, children less than 12 months old, or adults over the age of 65.

Glatt said for these groups especially, its important to make an appointment with a physician as soon as flu symptoms come on. Theyll be able to prescribe an appropriate antiviral medication to help relieve symptoms and clear the virus out of your body as fast as possible. (This is also good general advice, as doctors can prescribe medications like Tamiflu to help reduce the severity and length of the illness.)

Other than that, get lots of rest, drink fluids and monitor your symptoms. While you may be miserable for a few days, your body will fight the flu the best it can.

Read this article:
This Is Your Body On The Flu - HuffPost

The presence of the fungusAspergillushas forced theclosingof 11 operating rooms at Seattle Childrens Hospital, marking the second such closure in a year. All 14 of the hospitals operating rooms will be closed later in the week, said hospital spokeswoman Kathryn Mueller.

"On November 10, routine air test results revealed the presence ofAspergillusin the air in 3 of our operating rooms and 2 procedural areas," Mueller said. "The rooms in whichAspergilluswas detected have been closed. We are also investigating 2 new potentialAspergillussurgical site infections."

The hospital has had to postpone some surgeries and move others to different hospitals.Aspergillusis a fungus whose spores are present in the air and can cause illnesses in people with weakened immune systems, damaged lungs, and asthma. Infections caused byAspergillusincludeinvasive aspergillosis,ABPACPA, and aspergilloma.

Seattle Childrens Hospital says that the fungus has infected at least 1 patient, and possibly 2. This is the second time the fungus has been discovered in the hospitals operating rooms. The previousAspergillusoutbreak inMayled to at least 5 infections and 1 death.

Hospital officials blame the presence ofAspergillusin the operating rooms on deficiencies in ventilation and purification systems.

AnarticleinHPAC Engineeringnotes that hospitals consume much more energy than buildings and facilities in other industries of similar size. More energy is therefore needed to ventilate and purify the air.

Healthcare facilities that may not be properly ventilated, designed, or controlled can lead to the spread of airborne pathogens throughout the facility, according to the article. Hospital patients who have compromised immune systems and are more susceptible to infection will likely be infected and can spread pathogens to the rest of the hospital.

The article, which ran last year, also focused on the importance of a good filtering system in facilities and touts the benefits of bipolar ionization systems. They create negative and positive ions which then react with oxygen and water vapor within the air stream, creating free radicals. These free radicals in turn create chemical changes, which can damage viruses, bacteria and other microorganisms that often cause infections within a hospital. Even with this kind of system, filter media is still necessary to remove larger particles from the air stream. A filter media is anything in a filter that changes the quality of whats being filtered.

The Infectious Diseases Society of America (IDSA) recommends that the response toAspergillusinfection should involve submitting tissue and fluid specimens for histopathologic, cytologic, and culture examination to diagnose invasive aspergillosis. However, molecular techniques, such as DNA sequencing, should be used to identifyAspergillusspecies in cases that involve either isolates with atypical growth or concern for resistance, the IDSA recommends.

Astudythis year inAntimicrobial Resistance & Infection Controlnoted that the construction work at hospitalswhich seems to be happeningmore and morecan help breed invasive aspergillosis (IA)infection.

Investigators with the University of Ulsan College of Medicine in South Korea, wrote: Airborne fungal spore levels tended to be higher during the period with heavier construction works involving demolition and excavation, during which the incidence of IA was significantly higher as well.

They argued that airborne fungal spore levelsshould be monitored when constructions taking place in hospitals with patients who have compromised immune systems.

Go here to see the original:
Aspergillus Endangers Children at Hospital for Second Time This Year - Infection Control Today